Malaria and tuberculosis (TB) are two major global diseases mostly affecting the developing
countries. Their treatment is often complex because of the drugs used, multidrug resistance …

Rifabutin is a spiro-piperidyl-rifamycin structurally closely related to rifampicin that shares
many of its properties. We attempted to address the reasons why this drug, which was …

Seit der Veröffentlichung der Empfehlungen des DZK zur medikamentösen Therapie der
Tuberkulose (TB) 2001 sowie zur Chemoprävention der latenten tuberkulösen Infektion …

Objectives Drug-resistant TB remains a public health challenge. Rifamycins are among the
most potent anti-TB drugs. They are known to target the RpoB subunit of RNA polymerase; …

BACKGROUND Irritable bowel syndrome (IBS) is a common chronic non-organic disease of
the digestive system. Berberine (BBR) has been used to treat patients with IBS, but the …

Failure of first-line chemotherapy to cure tuberculosis (TB) patients occurs, in part, because
of the development of resistance to isoniazid (INH) and rifampicin (RIF) the two most …

Introduction: Rifabutin, a rifamycin of equivalent potency to rifampicin, has several
advantages in its pharmacokinetic and toxicity profile, particularly in HIV co-infected patients …

Although humans and microbes are inseparable, our knowledge and understanding of the
majority of microbes that help keep us alive and well is in desperate need of further …

OBJECTIVE: We investigated the efficacy of rifabutin (RFB)-containing regimens for the
treatment of RFB-susceptible, multidrug-resistant tuberculosis (MDR-TB). METHODS: From …

Historically, mycobacterial infections have been associated with signifi cant morbidity and
mortality worldwide. In particular, Mycobacterium tuberculosis is a highly successful human …